Amidst the global outbreak of COVID-19, we maintain our Buy rating on Healthia which has not reported any significant coronavirus-related disruption, based on their businesses categorised as essential community services.
Following a strong first year of operation since consolidating the various allied healthcare businesses together, Healthia performed well at an operational level to deliver sound financial returns through FY19.
The sound performance has been backed up through H1 of FY20 where Healthia increased revenue by 50% and EBITDA by 33% over the corresponding period for the year prior and declared a maiden dividend for shareholders.
This is only a brief excerpt of the report. To download it in full, simply register for free below.